REDUCTION IN LEFT VENTRICULAR OUTFLOW TRACT GRADIENT WITH MAVACAMTEN (MYK-461) IN SYMPTOMATIC OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY PATIENTS (PIONEER-HCM)

In obstructive hypertrophic cardiomyopathy (oHCM) LV hypertrophy, reduced compliance, and hyperdynamic function result in dyspnea, fatigue, and limited exercise capacity. Mavacamten is an oral, allosteric modulator of cardiac myosin that targets an underlying biomechanical abnormality in HCM and was